ClinicalTrials.gg
Not yet recruitingNCT07728318Updated Oct 29, 2026

Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients

An interventional study of Tirzepatide + Standard Therapy (Intervention Group) and Standard Oral Antidiabetic Drugs (OADs) in Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, sponsored by Akhtar Saeed Medical and Dental College. Not yet recruiting. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Akhtar Saeed Medical and Dental College · Not applicable, Interventional, and Treatment

How we know · 2 judgments

Updated Oct 29, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
30 Years to 80 Years
Sex
All
01

Study summary

Type 2 Diabetes Mellitus (T2DM) is a progressive metabolic disease, often compounded by obesity, that leads to serious long-term health complications. While traditional antidiabetic medications help manage blood sugar, many patients continue to struggle with uncontrolled diabetes and excess weight. Newer therapies, such as dual GIP/GLP-1 receptor agonists like Tirzepatide, have demonstrated significant efficacy in lowering blood glucose (HbA1c) and body weight in global clinical trials. However, real-world data regarding its efficacy, safety, and patient-reported satisfaction in South Asian populations, particularly in Pakistan, remains limited. This 6-month, quasi-experimental interventional study aims to compare the clinical outcomes and patient-reported satisfaction of once-weekly subcutaneous Tirzepatide (combined with standard oral antidiabetic therapy) versus standard therapy alone in obese patients with Type 2 Diabetes. A total of 52 eligible participants will be randomly allocated into two groups. Group 1 will receive standard oral antidiabetic treatment, while Group 2 will receive once-weekly Tirzepatide with dose escalation (starting at 2.5 mg monthly, increasing to 5 mg, and maintaining at 7.5 mg) alongside standard treatment. Primary evaluations will measure changes in HbA1c and body weight from baseline to 6 months. Secondary objectives include monitoring the frequency and severity of gastrointestinal side effects fortnightly and evaluating patient treatment satisfaction at 6 months using the validated Diabetes Treatment Satisfaction Questionnaire (DTSQ).

02

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
03

In context

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's planned enrollment of 52 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Akhtar Saeed Medical and Dental College is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients aged 30 to 80 years with diagnosed Type 2 Diabetes Mellitus.
  2. Uncontrolled diabetes with ≥ 7.0%.
  3. Obesity defined as (BMI) ≥ 25 kg/m² (Asian population threshold) or waist circumference > 90 cm in men or > 80 cm in women.
  4. History of taking oral antidiabetic drugs (OADs) for > 1 year.

Exclusion criteria

Exclusion Criteria:

  1. Patients currently or previously taking GLP-1 receptor agonists or weight loss medications.
  2. Patients currently receiving insulin therapy.
  3. Patients taking DPP-4 inhibitors.
  4. Pregnant or lactating females.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Active comparator
    Standard Therapy (Control Group)

    Participants will continue their baseline standard oral antidiabetic drug (OAD) therapy (metformin with or without SGLT2 inhibitors like dapagliflozin or empagliflozin) for 6 months . All participants will also receive monthly dietary counseling from a nutritionist and a recommended walking regimen of 30 minutes, 5 days a week.

    Other: Standard Oral Antidiabetic Drugs (OADs)

  • Experimental
    Tirzepatide + Standard Therapy (Intervention Group)

    Participants will receive subcutaneous once-weekly Tirzepatide added to their baseline standard oral antidiabetic drug (OAD) therapy for 6 months . Tirzepatide will be initiated at 2.5 mg once weekly for Month 1, escalated to 5 mg once weekly for Month 2, and maintained at 7.5 mg once weekly for Months 3-6 . Participants will also receive monthly dietary counseling and a recommended walking regimen.

    Other: Tirzepatide + Standard Therapy (Intervention Group)

Interventions

  • OtherTirzepatide + Standard Therapy (Intervention Group)

    Administered subcutaneously once weekly with dose escalation: Month 1: 2.5 mg once weekly Month 2: 5 mg once weekly Months 3 to 6: Maintenance dose of 7.5 mg once weekly'

  • OtherStandard Oral Antidiabetic Drugs (OADs)

    Standard oral antidiabetic therapy including Metformin (500mg, 1000mg, or 1500mg daily) with or without SGLT2 inhibitors (Dapagliflozin or Empagliflozin) maintained throughout the 6-month study period

This study also gives TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change in Glycemic Control (HbA1c)

    Mean change in HbA1c percentage from baseline to evaluate efficacy in glycemic control (a reduction of ≥1% is defined as clinically effective).

    Time frame: Baseline, 3 months, and 6 months

  2. Change in Body Weight

    Mean percentage change in body weight from baseline (a weight reduction of ≥5% is defined as clinically effective).

    Time frame: Baseline and monthly up to 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2027; primary completion for Jan 2028, 1 month later.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 1 month is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: start Aug 2026 → Dec 2027, primary completion Jan 2027 → Jan 2028 and completion May 2027 → May 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2026
First posted
Jul 27, 2026
StartEst.
Dec 12, 2027was Aug 2026
Primary completionEst.
Jan 12, 2028was Jan 2027
CompletionEst.
May 12, 2028was May 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 12, 2026→Dec 12, 2027
Oct 29, 2026
Primary completion
Jan 12, 2027→Jan 12, 2028
Oct 29, 2026
Study completion
May 12, 2027→May 12, 2028
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Start date Aug 12, 2026→Dec 12, 2027
    Primary completion Jan 12, 2027→Jan 12, 2028
    Study completion May 12, 2027→May 12, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07728318
Lead sponsor
Akhtar Saeed Medical and Dental College
Responsible party
Dr. Shameen Hashmi (Principal Investigator, Akhtar Saeed Medical and Dental College) — Principal investigator
First posted
Jul 27, 2026
Start date
Dec 12, 2027 (estimated)
Primary completion
Jan 12, 2028 (estimated)
Completion
May 12, 2028 (estimated)
Last update
Oct 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion